These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

532 related items for PubMed ID: 15784036

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
    Angeli P, Volpin R, Piovan D, Bortoluzzi A, Craighero R, Bottaro S, Finucci GF, Casiglia E, Sticca A, De Toni R, Pavan L, Gatta A.
    Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
    [Abstract] [Full Text] [Related]

  • 3. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
    Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, Sticca A, Caregaro L, Maffei-Faccioli A, Gatta A.
    Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
    [Abstract] [Full Text] [Related]

  • 4. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
    Wong F, Pantea L, Sniderman K.
    Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
    [Abstract] [Full Text] [Related]

  • 5. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites.
    Kalambokis G, Fotopoulos A, Economou M, Pappas K, Tsianos EV.
    J Hepatol; 2007 Feb; 46(2):213-21. PubMed ID: 17156883
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome.
    Skagen C, Einstein M, Lucey MR, Said A.
    J Clin Gastroenterol; 2009 Aug; 43(7):680-5. PubMed ID: 19238094
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.
    Singh V, Dhungana SP, Singh B, Vijayverghia R, Nain CK, Sharma N, Bhalla A, Gupta PK.
    J Hepatol; 2012 Feb; 56(2):348-54. PubMed ID: 21749847
    [Abstract] [Full Text] [Related]

  • 10. Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.
    Singh V, Singh A, Singh B, Vijayvergiya R, Sharma N, Ghai A, Bhalla A.
    Am J Gastroenterol; 2013 Apr; 108(4):560-7. PubMed ID: 23419385
    [Abstract] [Full Text] [Related]

  • 11. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study.
    Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A.
    Hepatology; 2003 Jul; 38(1):238-43. PubMed ID: 12830007
    [Abstract] [Full Text] [Related]

  • 12. The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study.
    Tandon P, Tsuyuki RT, Mitchell L, Hoskinson M, Ma MM, Wong WW, Mason AL, Gutfreund K, Bain VG.
    Liver Int; 2009 Feb; 29(2):169-74. PubMed ID: 18492024
    [Abstract] [Full Text] [Related]

  • 13. The effects of treatment with octreotide, diuretics, or both on portal hemodynamics in nonazotemic cirrhotic patients with ascites.
    Kalambokis G, Economou M, Kosta P, Papadimitriou K, Tsianos EV.
    J Clin Gastroenterol; 2006 Apr; 40(4):342-6. PubMed ID: 16633107
    [Abstract] [Full Text] [Related]

  • 14. Effect of subcutaneous administration of octreotide on endogenous vasoactive systems and renal function in cirrhotic patients with ascites.
    Sàbat M, Guarner C, Soriano G, Bulbena O, Novella MT, Ortiz J, Ricart E, Villanueva C, Rosello J, Rodríguez J, Balanzó J.
    Dig Dis Sci; 1998 Oct; 43(10):2184-9. PubMed ID: 9790452
    [Abstract] [Full Text] [Related]

  • 15. Effects of a long-acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: a randomized, double-blind, controlled trial.
    Ottesen LH, Aagaard NK, Kiszka-Kanowitz M, Rehling M, Henriksen JH, Pedersen EB, Flyvbjerg A, Bendtsen F.
    Hepatology; 2001 Sep; 34(3):471-7. PubMed ID: 11526531
    [Abstract] [Full Text] [Related]

  • 16. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis.
    La Villa G, Barletta G, Pantaleo P, Del Bene R, Vizzutti F, Vecchiarino S, Masini E, Perfetto F, Tarquini R, Gentilini P, Laffi G.
    Hepatology; 2001 Jul; 34(1):19-27. PubMed ID: 11431729
    [Abstract] [Full Text] [Related]

  • 17. Enhanced external counterpulsation: a new technique to augment renal function in liver cirrhosis.
    Werner D, Trägner P, Wawer A, Porst H, Daniel WG, Gross P.
    Nephrol Dial Transplant; 2005 May; 20(5):920-6. PubMed ID: 15788437
    [Abstract] [Full Text] [Related]

  • 18. Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.
    Appenrodt B, Wolf A, Grünhage F, Trebicka J, Schepke M, Rabe C, Lammert F, Sauerbruch T, Heller J.
    Liver Int; 2008 Aug; 28(7):1019-25. PubMed ID: 18410283
    [Abstract] [Full Text] [Related]

  • 19. Effects of nadolol on systemic and renal hemodynamics in patients with renoparenchymal hypertension and various degrees of renal function.
    Valvo E, Gammaro L, Bedogna V, Cavaggioni M, Tonon M, Lupo A, Loschiavo C, Tessitore N, Oldrizzi L, Rugiu G.
    Int J Clin Pharmacol Ther Toxicol; 1986 Apr; 24(4):202-6. PubMed ID: 3710633
    [Abstract] [Full Text] [Related]

  • 20. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.
    Wong F, Raina N, Richardson R.
    Gut; 2010 Mar; 59(3):381-6. PubMed ID: 19710033
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.